CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB1,2. Here we show that patients with NSCLC who have mutations in the STK11 and/or KEAP1 tumour suppressor genes derived clinical benefit from dual ICB with the PD-L1 inhibitor durvalumab and the CTLA4 inhibitor tremelimumab, but not from durvalumab alone, when added to chemotherapy in the randomized phase III POSEIDON trial3. Unbiased genetic screens identified loss of both of these tumour suppressor genes as independent drivers of resistance to PD-(L)1 inhibition, and showed that loss of Keap1 was the strongest genomic predictor of dual ICB efficacy—a finding that was confirmed in several mouse models of Kras-driven NSCLC. In both mouse models and patients, KEAP1 and STK11 alterations were associated with an adverse tumour microenvironment, which was characterized by a preponderance of suppressive myeloid cells and the depletion of CD8+ cytotoxic T cells, but relative sparing of CD4+ effector subsets. Dual ICB potently engaged CD4+ effector cells and reprogrammed the tumour myeloid cell compartment towards inducible nitric oxide synthase (iNOS)-expressing tumoricidal phenotypes that—together with CD4+ and CD8+ T cells—contributed to anti-tumour efficacy. These data support the use of chemo-immunotherapy with dual ICB to mitigate resistance to PD-(L)1 inhibition in patients with NSCLC who have STK11 and/or KEAP1 alterations. Alterations in the tumour suppressor genes STK11 and/or KEAP1 can identify patients with advanced non-small-cell lung cancer who are likely to benefit from combinations of PD-(L)1 and CTLA4 immune checkpoint inhibitors added to chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previously, we conducted an in vivo CRISPR screen in the MC38 mouse model to identify genes that, when knocked out, drove immune evasion and resistance to anti–PD-1 treatment. STK11 was one of several identified genes in the screen that caused resistance to immune checkpoint blockade (20).”
From TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the MC38 syngeneic model, which is KRAS wild-type, loss of STK11 alone is sufficient to drive resistance to anti–PD-1 (20).”
From TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“STK11/LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors9,10 and KRASG12C inhibitors3,4.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“STK11/LKB1 and KEAP1 mutations can reshape a colder TME and suppress the infiltration of T cells [157].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [157]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · cited 1×
“%) levels 4 .”
Self-citationImproved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
TIMER2.0 for analysis of tumor-infiltrating immune cells
Li, T., Fu, J., Zeng, Z., Cohen, D., Li, J., Chen, Q., Li, B., & Liu, X. S. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa407 · Cited by 5,209
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637 · cited 1×
“First, all possible 20-bp sgRNAs (using an NGG PAM) targeting each gene of interest were identified and scored for predicted on-target cutting efficiency using an available sgRNA design/scoring algorithm 68 .”
xCell: digitally portraying the tissue cellular heterogeneity landscape
Aran, D., Hu, Z., & Butte, A. J. (2017) · Genome Biology · doi:10.1186/s13059-017-1349-1 · Cited by 4,397 · cited 10×
“C57BL/6J mice were treated by intraperitoneal injection with anti-mPD-1 (BioXCell, BE0146) or anti-IgG2a (BioXCell, BE0089) at 5 mg per kg or 10 mg per kg, twice per week for two weeks.”
InfluentialAnalysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519 · cited 2×
“TMB was measured by Foundation Medicine as described previously 52 .”
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
Self-citationLi, W., Xu, H., Xiao, T., Cong, L., Love, M. I., Zhang, F., Irizarry, R. A., Liu, J. S., Brown, M., & Liu, X. S. (2014) · Genome Biology · doi:10.1186/s13059-014-0554-4 · Cited by 2,684 · cited 2×
“6,13,49,63).”
InfluentialOncoKB: A Precision Oncology Knowledge Base
Chakravarty, D., Gao, J., Phillips, S., Kundra, R., Zhang, H., Wang, J., Rudolph, J. E., Yaeger, R., Soumerai, T., Nissan, M. H., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00011 · Cited by 2,589
Self-citationPan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157
AACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641
Self-citationPaz-Ares, L., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30641-0 · Cited by 1,366 · cited 1×
“…phenotype associated with inactivation of these TSGs. Inhibitors of a second immune checkpoint, the CTLA4 pathway (CTLA4i), have also improved clinical outcomes for some patients with NSCLC when combined with PD-(L)1i (dual immune checkpoint blockade or ICB), with or without chemotherapy 1,3,20 .”
Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A. B., Mezquita, L., Thai, A. A., Mascaux, C., Couraud, S., Veillon, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz167 · Cited by 1,354
Self-citationDistinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · cited 1×
“This finding is consistent with previous reports of CD4 + T cell phenotypic expansion in response to CTLA4 pathway blockade 39,40 .”
Gainor, J. F., Shaw, A. T., Sequist, L. V., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,250
Self-citationIn vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147 · cited 1×
“Genomic DNA isolation and sequencing were performed as previously described 62 .”
LKB1 modulates lung cancer differentiation and metastasis
Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., et al. (2007) · Nature · doi:10.1038/nature06030 · Cited by 1,064
Self-citationSkoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936 · cited 3×
“6a–c), consistent with their previously reported immunosuppressive phenotype 5,12,13,37 .”
Self-citationConditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
DuPage, M., Dooley, A. L., & Jacks, T. (2009) · Nature Protocols · doi:10.1038/nprot.2009.95 · Cited by 894
Koyama, S., Akbay, E. A., Li, Y. Y., Aref, A. R., Skoulidis, F., Herter-Sprie, G. S., Buczkowski, K. A., Liu, Y., Awad, M. M., Denning, W. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1439 · Cited by 640
Self-citationFc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592 · cited 1×
“Furthermore, although our experiments were not designed to address the possible contribution of direct FcγR-mediated innate immune remodelling, this might, at least partially, affect anti-tumour efficacy in clinical settings 46–48 .”
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Yarchoan, M., Albacker, L. A., Hopkins, A. C., Montesion, M., Murugesan, K., Vithayathil, T. T., Zaidi, N., Azad, N. S., Laheru, D. A., Frampton, G. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126908 · Cited by 545
Self-citationSuppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
Kitajima, S., Ivanova, E., Guo, S., Yoshida, R., Campisi, M., Sundararaman, S. K., Tange, S., Mitsuishi, Y., Thai, T. C., Masuda, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0689 · Cited by 526
Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR
Li, W., Köster, J., Xu, H., Chen, C.-H., Xiao, T., Liu, J. S., Brown, M., & Liu, X. S. (2015) · Genome Biology · doi:10.1186/s13059-015-0843-6 · Cited by 507
Arbour, K. C., Jordan, E., Kim, H. R., Dienstag, J., Yu, H. A., Sanchez-Vega, F., Lito, P., Berger, M., Solit, D. B., Hellmann, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1841 · Cited by 466
Self-citationJohnson, M. L., Cho, B. C., Luft, A., Alatorre-Alexander, J., Geater, S. L., Laktionov, K., Kim, S.-W., Ursol, G., Hussein, M., Lim, F. L., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00975 · Cited by 463 · cited 2×
“…phenotype associated with inactivation of these TSGs. Inhibitors of a second immune checkpoint, the CTLA4 pathway (CTLA4i), have also improved clinical outcomes for some patients with NSCLC when combined with PD-(L)1i (dual immune checkpoint blockade or ICB), with or without chemotherapy 1,3,20 .”
Carthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., Ku, G., Troncoso, P., Logothetis, C. J., Allison, J. P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0569 · Cited by 460
A neutrophil response linked to tumor control in immunotherapy
Gungabeesoon, J., Gort-Freitas, N. A., Kiss, M., Bolli, E., Messemaker, M., Siwicki, M., Hicham, M., Bill, R., Koch, P., Cianciaruso, C., et al. (2023) · Cell · doi:10.1016/j.cell.2023.02.032 · Cited by 412
Self-citationBrahmer, J. R., Lee, J.-S., Ciuleanu, T.-E., Bernabe Caro, R., Nishio, M., Urban, L., Audigier-Valette, C., Lupinacci, L., Sangha, R., Pluzanski, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01503 · Cited by 406
Self-citationRicciuti, B., Arbour, K. C., Lin, J. J., Vajdi, A., Vokes, N., Hong, L., Zhang, J., Tolstorukov, M. Y., Li, Y. Y., Spurr, L. F., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.013 · Cited by 394
Self-citationBiton, J., Mansuet-Lupo, A., Pécuchet, N., Alifano, M., Ouakrim, H., Arrondeau, J., Boudou-Rouquette, P., Goldwasser, F., Leroy, K., Goc, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0163 · Cited by 351
Self-citationde Castro, G., Kudaba, I., Wu, Y.-L., Lopes, G., Kowalski, D. M., Turna, H. Z., Caglevic, C., Zhang, L., Karaszewska, B., Laktionov, K. K., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.21.02885 · Cited by 329
CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours
Kruse, B., Buzzai, A. C., Shridhar, N., Braun, A. D., Gellert, S., Knauth, K., Pozniak, J., Peters, J., Dittmann, P., Mengoni, M., et al. (2023) · Nature · doi:10.1038/s41586-023-06199-x · Cited by 316
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants
Hirschhorn, D., Budhu, S., Kraehenbuehl, L., Gigoux, M., Schröder, D., Chow, A., Ricca, J. M., Gasmi, B., De Henau, O., Mangarin, L. M. B., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.007 · Cited by 303
Self-citationNegrao, M. V., Skoulidis, F., Montesion, M., Schulze, K., Bara, I., Shen, V., Xu, H., Hu, S., Sui, D., Elamin, Y. Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002891 · Cited by 294
Self-citationGalan-Cobo, A., Sitthideatphaiboon, P., Qu, X., Poteete, A., Pisegna, M. A., Tong, P., Chen, P.-H., Boroughs, L. K., Rodriguez, M. L. M., Zhang, W., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3527 · Cited by 292 · cited 1×
“…that owing to the partially shared biology between Keap1 and Stk11 loss, including the upregulation of a NRF2-driven transcriptional program 18,36 , dual ICB might represent an effective therapeutic strategy that applies to both oncogenotypes, as supported by subgroup analyses from POSEIDON.”
Self-citationWang, R., Dang, M., Harada, K., Han, G., Wang, F., Pool Pizzi, M., Zhao, M., Tatlonghari, G., Zhang, S., Hao, D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-1125-8 · Cited by 267
Self-citationChiou, S.-H., Winters, I. P., Wang, J., Naranjo, S., Dudgeon, C., Tamburini, F. B., Brady, J. J., Yang, D., Grüner, B. M., Chuang, C.-H., et al. (2015) · Genes & Development · doi:10.1101/gad.264861.115 · Cited by 264
Self-citationWohlhieter, C. A., Richards, A. L., Uddin, F., Hulton, C. H., Quintanal-Villalonga, À., Martin, A., de Stanchina, E., Bhanot, U., Asher, M., Shah, N. S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108444 · Cited by 246
Self-citationPapillon-Cavanagh, S., Doshi, P., Dobrin, R., Szustakowski, J., & Walsh, A. M. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000706 · Cited by 235
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
Olson, D. J., Eroglu, Z., Brockstein, B., Poklepovic, A. S., Bajaj, M., Babu, S., Hallmeyer, S., Velasco, M., Lutzky, J., Higgs, E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00079 · Cited by 221
Best, S. A., De Souza, D. P., Kersbergen, A., Policheni, A. N., Dayalan, S., Tull, D., Rathi, V., Gray, D. H., Ritchie, M. E., McConville, M. J., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.006 · Cited by 217
MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma
Qian, Y., Galan-Cobo, A., Guijarro, I., Dang, M., Molkentine, D., Poteete, A., Zhang, F., Wang, Q., Wang, J., Parra, E., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.015 · Cited by 193
Self-citationThe AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC
Hollstein, P. E., Eichner, L. J., Brun, S. N., Kamireddy, A., Svensson, R. U., Vera, L. I., Ross, D. S., Rymoff, T. J., Hutchins, A., Galvez, H. M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1261 · Cited by 168
NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes
Singh, A., Daemen, A., Nickles, D., Jeon, S.-M., Foreman, O., Sudini, K., Gnad, F., Lajoie, S., Gour, N., Mitzner, W., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1985 · Cited by 167
West, H. J., McCleland, M., Cappuzzo, F., Reck, M., Mok, T. S., Jotte, R. M., Nishio, M., Kim, E., Morris, S., Zou, W., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003027 · Cited by 153
Rogers, Z. N., McFarland, C. D., Winters, I. P., Naranjo, S., Chuang, C.-H., Petrov, D., & Winslow, M. M. (2017) · Nature Methods · doi:10.1038/nmeth.4297 · Cited by 147
Self-citationDeng, J., Thennavan, A., Dolgalev, I., Chen, T., Li, J., Marzio, A., Poirier, J. T., Peng, D. H., Bulatovic, M., Mukhopadhyay, S., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00208-6 · Cited by 140
Self-citationMapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice
Rogers, Z. N., McFarland, C. D., Winters, I. P., Seoane, J. A., Brady, J. J., Yoon, S., Curtis, C., Petrov, D. A., & Winslow, M. M. (2018) · Nature Genetics · doi:10.1038/s41588-018-0083-2 · Cited by 132
Self-citationThe genetics and biology of KRAS in lung cancer
Westcott, P. M. K., & To, M. D. (2013) · Chinese Journal of Cancer · doi:10.5732/cjc.012.10098 · Cited by 116
Vokes, N. I., Liu, D., Ricciuti, B., Jimenez-Aguilar, E., Rizvi, H., Dietlein, F., He, M. X., Margolis, C. A., Elmarakeby, H. A., Girshman, J., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00171 · Cited by 114
Self-citationAn LKB1–SIK Axis Suppresses Lung Tumor Growth and Controls Differentiation
Murray, C. W., Brady, J. J., Tsai, M. K., Li, C., Winters, I. P., Tang, R., Andrejka, L., Ma, R. K., Kunder, C. A., Chu, P., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1237 · Cited by 111 · cited 1×
“Inactivation of several TSGs—including Stk11 and, to a lesser extent, Keap1 —promoted in vivo tumour growth in the absence of therapy, as reported previously 33–35 (Extended Data Fig.”
Sitthideatphaiboon, P., Galan-Cobo, A., Negrao, M. V., Qu, X., Poteete, A., Zhang, F., Liu, D. D., Lewis, W. E., Kemp, H. N., Lewis, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2859 · Cited by 111
Self-citationMarzio, A., Kurz, E., Sahni, J. M., Di Feo, G., Puccini, J., Jiang, S., Hirsch, C. A., Arbini, A. A., Wu, W. L., Pass, H. I., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.005 · Cited by 110
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
Kitajima, S., Tani, T., Springer, B. F., Campisi, M., Osaki, T., Haratani, K., Chen, M., Knelson, E. H., Mahadevan, N. R., Ritter, J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.015 · Cited by 107
Li, R., Salehi‐Rad, R., Crosson, W. P., Momcilovic, M., Lim, R. J., Ong, S. L., Huang, Z. L., Zhang, T.-H., Abascal, J. W., Dumitras, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3564 · Cited by 105
Waight, J. D., Chand, D., Dietrich, S., Gombos, R., Horn, T., Gonzalez, A. M., Manrique, M., Swiech, L., Morin, B., Brittsan, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.005 · Cited by 104
Paz-Ares, L. G., Ciuleanu, T.-E., Cobo, M., Bennouna, J., Schenker, M., Cheng, Y., Juan-Vidal, O., Mizutani, H., Lingua, A., Reyes-Cosmelli, F., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.10.014 · Cited by 104
Self-citationWei, S. C., Sharma, R., Anang, N.-A. A. S., Levine, J. H., Zhao, Y., Mancuso, J. J., Setty, M., Sharma, P., Wang, J., Pe’er, D., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.004 · Cited by 97
Alessi, J. V., Elkrief, A., Ricciuti, B., Wang, X., Cortellini, A., Vaz, V. R., Lamberti, G., Frias, R. L., Venkatraman, D., Fulgenzi, C. A. M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.01.091 · Cited by 97 · cited 2×
“…LKB1 protein that functions as a master regulator of tumour cell metabolism, growth and polarity; and KEAP1 , which encodes an adaptor protein that is crucial for the ubiquitination and proteasomal degradation of NRF2 and is thus a key regulator of antioxidant and cytoprotective responses 5–11 .”
Self-citationWinters, I. P., Chiou, S.-H., Paulk, N. K., McFarland, C. D., Lalgudi, P. V., Ma, R. K., Lisowski, L., Connolly, A. J., Petrov, D. A., Kay, M. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01519-y · Cited by 94
Self-citationKaufman, J. M., Amann, J. M., Park, K., Arasada, R. R., Li, H., Shyr, Y., & Carbone, D. P. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000173 · Cited by 87 · cited 1×
“…levels and overall immune infiltrate (ImmuneScore) were estimated as gene signatures using XCell 57 and plotted according to the presence of STK11 and/or KEAP1 somatic mutations or functional status using previously validated signatures for LKB1 deficiency 58 or NRF2 transcriptional activation 8 .”
Yofe, I., Landsberger, T., Yalin, A., Solomon, I., Costoya, C., Demane, D. F., Shah, M., David, E., Borenstein, C., Barboy, O., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00447-1 · Cited by 83
Parra, E. R., Ferrufino-Schmidt, M. C., Tamegnon, A., Zhang, J., Solis, L., Jiang, M., Ibarguen, H., Haymaker, C., Lee, J. J., Bernatchez, C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88156-0 · Cited by 65
Self-citationImmune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer
Parra, E. R., Zhang, J., Jiang, M., Tamegnon, A., Pandurengan, R. K., Behrens, C., Solis, L. M., Haymaker, C., Heymach, J. V., Moran, C. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37905-y · Cited by 56
Self-citationCummings, A. L., Gukasyan, J., Lu, H. Y., Grogan, T., Sunga, G. M., Fares, C. M., Hornstein, N. J., Zaretsky, J. M., Carroll, J., Bachrach, B., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00140-1 · Cited by 47
Self-citationGarassino, M. C., Gadgeel, S., Novello, S., Halmos, B., Felip, E., Speranza, G., Hui, R., Garon, E. B., Horinouchi, H., Sugawara, S., et al. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100431 · Cited by 46
Self-citationProulx-Rocray, F., Routy, B., Nassabein, R. M., Belkaïd, W., Tran‐Thanh, D., Malo, J., Tonneau, M., Ouarzadi, O. E., Florescu, M., Tehfe, M. A., et al. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100767 · Cited by 38
Quantitative In Vivo Analyses Reveal a Complex Pharmacogenomic Landscape in Lung Adenocarcinoma
Li, C., Lin, W.-Y., Rizvi, H. A., Cai, H., McFarland, C. D., Rogers, Z. N., Yousefi, M., Winters, I. P., Rudin, C. M., Petrov, D. A., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0716 · Cited by 24
Self-citationChiou, S., Kim-Kiselak, C., Risca, V. I., Heimann, M., Chuang, C.-H., Burds, A. A., Greenleaf, W. J., Jacks, T., Feldser, D. M., & Winslow, M. M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.031 · Cited by 13
Self-citationSchmidt, S., Akhave, N. S., Knightly, R., Reuben, A., Vokes, N. I., Zhang, J., Li, J., Fujimoto, J., Byers, L. A., Sánchez‐Espiridión, B., et al. (2022) · JCO Clinical Cancer Informatics · doi:10.1200/cci.22.00040 · Cited by 7
Self-citation
Cited by
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Tumour and microenvironment crosstalk in NSCLC progression and response to therapy
Rahal, Z., Darzi, R. E., Moghaddam, S. J., Cascone, T., & Kadara, H. N. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01021-1 · Cited by 122
Self-citationGong, Z., Du, M., Li, Y., Ye, B., Huang, Y., Gong, H., Wang, W., Chen, L., Ding, Z., & Zhang, P. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-02172-2 · Cited by 87
Wang, Y., Safi, M., Hirsch, F. R., Lu, S., Peters, S., Govindan, R., Rosell, R., Park, K., & Zhang, J. J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00979-8 · Cited by 84
Self-citationMariniello, A., Borgeaud, M., WEINER, M. H., Frisone, D., Kim, F., & Addeo, A. (2025) · BioDrugs · doi:10.1007/s40259-024-00700-2 · Cited by 78
Metadata
- Authors
- Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Galan-Cobo, A., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., Juan, J. M., Min, C., Yu, Y., Pan, X., Arbour, K. C., Vokes, N., Schmidt, S. T., Molkentine, D., Owen, D. H., Memmott, R., Patil, P. D., Marmarelis, M. E., Awad, M. M., Murray, J. C., Hellyer, J. A., Gainor, J. F., Dimou, A., Bestvina, C. M., Shu, C. A., Riess, J. W., Blakely, C. M., Pecot, C. V., Mezquita, L., Tabbó, F., Scheffler, M., Digumarthy, S., Mooradian, M. J., Sacher, A. G., Lau, S. C. M., Saltos, A. N., Rotow, J., Johnson, R. P., Liu, C., Stewart, T., Goldberg, S. B., Killam, J., Walther, Z., Schalper, K., Davies, K. D., Woodcock, M. G., Anagnostou, V., Marrone, K. A., Forde, P. M., Ricciuti, B., Venkatraman, D., Van Allen, E. M., Cummings, A. L., Goldman, J. W., Shaish, H., Kier, M., Katz, S., Aggarwal, C., Ni, Y., Azok, J. T., Segal, J., Ritterhouse, L., Neal, J. W., Lacroix, L., Elamin, Y. Y., Negrao, M. V., Le, X., Lam, V. K., Lewis, W. E., Kemp, H. N., Carter, B., Roth, J. A., Swisher, S., Lee, R., Zhou, T., Poteete, A., Kong, Y., Takehara, T., Paula, A. G., Parra Cuentas, E. R., Behrens, C., Wistuba, I. I., Zhang, J., Blumenschein, G. R., Gay, C., Byers, L. A., Gibbons, D. L., Tsao, A., Lee, J. J., Bivona, T. G., Camidge, D. R., Gray, J. E., Leighl, N. B., Levy, B., Brahmer, J. R., Garassino, M. C., Gandara, D. R., Garon, E. B., Rizvi, N. A., Scagliotti, G. V., Wolf, J., Planchard, D., Besse, B., Herbst, R. S., Wakelee, H. A., Pennell, N. A., Shaw, A. T., Jänne, P. A., Carbone, D. P., Hellmann, M. D., Rudin, C. M., Albacker, L., Mann, H., Zhu, Z., Lai, Z., Stewart, R., Peters, S., Johnson, M. L., Wong, K. K., Huang, A., Winslow, M. M., Rosen, M. J., Winters, I. P., Papadimitrakopoulou, V. A., Cascone, T., Jewsbury, P., & Heymach, J. V.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Foundation Medicine (United States) (US)
- Tango Therapeutics (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Cleveland Clinic (US)
- University of Pennsylvania (US)
- Dana-Farber Cancer Institute (US)
- Johns Hopkins University (US)
- Stanford University (US)
- Massachusetts General Hospital (US)
- Mayo Clinic (US)
- University of Chicago (US)
- Columbia University (US)
- UC Davis Comprehensive Cancer Center (US)
- University of California, San Francisco (US)
- UNC Lineberger Comprehensive Cancer Center (US)
- Hospital Clínic de Barcelona (ES)
- University Hospital Cologne (DE)
- Princess Margaret Cancer Centre (CA)
- NYU Langone’s Laura and Isaac Perlmutter Cancer Center (US)
- Moffitt Cancer Center (US)
- University of California San Diego (US)
- Yale University (US)
- North Shore University Hospital (US)
- University of Colorado Anschutz (US)
- University of California, Los Angeles (US)
- Icahn School of Medicine at Mount Sinai (US)
- Institut Gustave Roussy (FR)
- University of Colorado Cancer Center (US)
- Synthekine (US)
- University of Turin (IT)
- AstraZeneca (United States) (US)
- AstraZeneca (United Kingdom) (GB)
- Centre Hospitalier Universitaire Vaudois (CH)
- Sarah Cannon (US)
- Pfizer (United States) (US)
- Corresponding author
- Skoulidis, Ferdinandos
- Heymach, John V.
- ORCID
- Skoulidis, Ferdinandos
- Qian, Yu
- Galan-Cobo, Ana
- Le, John T.
- Montesion, Meagan
- Jahchan, Nadine
- Juan, Joseph M.
- Min, Chengyin
- Yu, Yi
- Pan, Xuewen
- Arbour, Kathryn C.
- Vokes, Natalie
- Schmidt, Stephanie T.
- Molkentine, David
- Owen, Dwight H.
- Patil, Pradnya D.
- Marmarelis, Melina E.
- Awad, Mark M.
- Murray, Joseph C.
- Hellyer, Jessica A.
- Gainor, Justin F.
- Bestvina, Christine M.
- Shu, Catherine A.
- Riess, Jonathan W.
- Blakely, Collin M.
- Pecot, Chad V.
- Mezquita, Laura
- Tabbó, Fabrizio
- Scheffler, Matthias
- Digumarthy, Subba
- Mooradian, Meghan J.
- Sacher, Adrian G.
- Lau, Sally C. M.
- Saltos, Andreas N.
- Rotow, Julia
- Liu, Corinne
- Stewart, Tyler
- Goldberg, Sarah B.
- Walther, Zenta
- Schalper, Kurt
- Davies, Kurtis D.
- Woodcock, Mark G.
- Anagnostou, Valsamo
- Marrone, Kristen A.
- Forde, Patrick M.
- Ricciuti, Biagio
- Venkatraman, Deepti
- Cummings, Amy L.
- Goldman, Jonathan W.
- Shaish, Hiram
- Kier, Melanie
- Katz, Sharyn
- Ni, Ying
- Segal, Jeremy
- Ritterhouse, Lauren
- Neal, Joel W.
- Lacroix, Ludovic
- Elamin, Yasir Y.
- Negrao, Marcelo V.
- Le, Xiuning
- Lam, Vincent K.
- Lewis, Whitney E.
- Roth, Jack A.
- Swisher, Stephen
- Lee, Richard
- Zhou, Teng
- Poteete, Alissa
- Takehara, Tomohiro
- Parra Cuentas, Edwin R.
- Behrens, Carmen
- Wistuba, Ignacio I.
- Zhang, Jianjun
- Blumenschein, George R.
- Gay, Carl
- Byers, Lauren A.
- Gibbons, Don L.
- Tsao, Anne
- Lee, J. Jack
- Bivona, Trever G.
- Camidge, D. Ross
- Levy, Benjamin
- Brahmer, Julie R.
- Garassino, Marina C.
- Gandara, David R.
- Garon, Edward B.
- Rizvi, Naiyer A.
- Scagliotti, Giorgio Vittorio
- Wolf, Jürgen
- Planchard, David
- Besse, Benjamin
- Herbst, Roy S.
- Wakelee, Heather A.
- Pennell, Nathan A.
- Shaw, Alice T.
- Jänne, Pasi A.
- Carbone, David P.
- Hellmann, Matthew D.
- Rudin, Charles M.
- Albacker, Lee
- Mann, Helen
- Lai, Zhongwu
- Stewart, Ross
- Peters, Solange
- Johnson, Melissa L.
- Wong, Kwok K.
- Huang, Alan
- Winslow, Monte M.
- Rosen, Michael J.
- Winters, Ian P.
- Papadimitrakopoulou, Vassiliki A.
- Cascone, Tina
- Heymach, John V.
- Venue
- Nature
- Published
- 2024-10-09
- Volume
- 635
- Issue
- 8038
- Pages
- 462-471
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC11560846
- OpenAlex
- W4403243250
- Cited by
- 194
- References
- 77
- Citations by year
- 2026: 97 · 2025: 92 · 2024: 5
- FWCI
- 33.22
- Type
- journal article
- Language
- en
- Update notices
- correction (2025-02-27)
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
- IRIS (submittedVersion, cc-by-nc-nd)
- SERVAL (Université de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- National Institutes of Health (5r01ca205150-04, 1s10od024977-01, UL1TR001863)
- National Cancer Institute (R01-CA205150, P50CA070907, P30CA008748, R01CA262469, R01CA276917, T32CA009172, P30CA016672, R01CA279452, P30CA016058, P30CA016042)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, PD-L1 inhibitors, Keap1, STK11, non-small cell lung cancer, immune checkpoint blockade, durvalumab, tremelimumab, drug resistance, tumor microenvironment, myeloid cells, CD4+ T cells, CD8+ T cells, inducible nitric oxide synthase, chemoimmunotherapy, predictive biomarkers
- MeSH terms
- Kelch-Like ECH-Associated Protein 1, Immune Checkpoint Inhibitors, AMP-Activated Protein Kinase Kinases, Animals, Antibodies, Monoclonal, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Mutation, T-Lymphocytes, Genes, Tumor Suppressor, Clinical Trials, Phase III as Topic, Protein Serine-Threonine Kinases, Drug Resistance, Neoplasm, Tumor Suppressor Proteins, Mice, Nitric Oxide Synthase Type II, Tumor Microenvironment, B7-H1 Antigen, CTLA-4 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.